Par Equity

"It’s clear that in 2021 businesses are stating that data quality has never been more important"

"Our technology is already making a significant impact within counter terror and child sexual abuse investigations in the UK, and we're excited to build on this momentum in mainland Europe and the US. We've built a great network of partners to support our ambitious growth plans, and our team will double in size during each of the next two years to support this growth."

"We are very pleased to have the continued support of our seed investors who have helped us shape and scale this revolutionary business from an idea to commercial launch ready. With this latest round of investment, we are scaling up commercialisation and production of Gii. We have now successfully launched our first product, Gii-Sens, into our beachhead market of Human Diagnostic Biosensors. Ultimately, this funding round will enable us to capitalise on being first to market world-wide with high performing, cost effective, application-specific 3D Graphene Foam, enabling better products."

"In funding the next stage of our growth we’ve found a partner with a depth of experience and connections across the industries we’re working in. We’ve access to Par Equity’s network and direct recent industry and technology knowledge. Their support will help ensure that we are able to build on our existing momentum to rapidly grow a successful business."

"We are delighted to continue working with Par Equity who have been very supportive of our company and our vision. This investment will enable us to continue to develop and commercialise our cutting-edge technology that addresses a major unmet need in the development of novel therapies that can significantly reduce costs of care and improve patient outcomes for millions of people worldwide."